title: BCG in management of superficial bladder cancer.
abstract: Superficial bladder cancer and particularly carcinoma in situ has the potential for invasiveness for which the treatment is cystectomy with a resultant disappointing 50 per cent five-year survival and urinary diversion with a certain diminished quality of life. BCG therapy is a new method of treating aggressive superficial bladder cancer with better response rates than conventional chemotherapy. It may be immunologically mediated and, if so, may be the first major success of a therapeutic modality that offers less morbidity than the currently standard options of surgery, radiotherapy, or chemotherapy.
authors.affiliation: Institute for Tuberculosis Research, Cook County Hospital, Chicago, Illinois.
authors.forename: P
authors.initials: P
authors.lastname: Guinan
authors.forename: R
authors.initials: R
authors.lastname: Crispen
authors.forename: M
authors.initials: M
authors.lastname: Rubenstein
mesh_terms: D000283:Administration, Intravesical; D000465:Algorithms; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine